NR 568 Advanced Pharmacology for AGPCNP
Final Actual Exam (Weeks 5–8) 2026/2027 |
Verified Questions
Chamberlain University College of Nursing | Verified Q&A | Graduate-Level Adult-
Gerontology Primary Care Nurse Practitioner Students
This comprehensive final actual exam set contains exactly 200 original questions designed to reinforce
the official NR 568 Advanced Pharmacology course objectives for Weeks 5–8. The questions rigorously
assess mastery of Cardiovascular and Endocrine Pharmacology; Respiratory, Gastrointestinal, and
Infectious Disease Pharmacology; Neurological, Psychiatric, and Pain Management Pharmacology; and
Geriatric Pharmacology, Polypharmacy, and Safe Prescribing Principles. Content is original and
constructed to promote advanced clinical prescribing proficiency, evidence-based decision-making, and
patient safety for Graduate-Level Adult-Gerontology Primary Care Nurse Practitioner students preparing
for the final actual examination in the 2026/2027 academic cycle. Rationales draw upon foundational
advanced pharmacology textbooks and current clinical practice guidelines from organizations such as the
AHA, ADA, IDSA, GOLD, GINA, AGS, and others.
Domain: Cardiovascular and Endocrine Pharmacology
1. A 68-year-old patient with heart failure with reduced ejection fraction is started on
sacubitril/valsartan. The AGPCNP understands that this agent’s primary mechanism
involves:
A. Selective beta-1 blockade reducing myocardial oxygen demand
B. Neprilysin inhibition combined with angiotensin receptor blockade
C. Direct inhibition of the sodium-potassium ATPase pump
D. Calcium channel blockade in vascular smooth muscle
Correct Answer: B
Rationale: Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor (ARNI). Sacubitril
inhibits neprilysin, increasing natriuretic peptides, while valsartan blocks AT1 receptors. This dual
action is guideline-directed for HFrEF per AHA/ACC recommendations and is covered in advanced
pharmacology curricula for heart failure management.
2. Which laboratory parameter requires the closest monitoring when initiating
dapagliflozin in a patient with type 2 diabetes and chronic kidney disease?
A. Serum potassium and estimated glomerular filtration rate
B. Fasting lipid profile
C. Serum calcium and phosphate
D. Thyroid-stimulating hormone
Correct Answer: A
Rationale: SGLT2 inhibitors such as dapagliflozin can cause volume depletion and modest declines in
eGFR upon initiation; potassium may also shift. Monitoring eGFR and electrolytes aligns with ADA and
KDIGO guidance and is emphasized in NR 568 endocrine and cardiovascular content.
3. A patient taking amiodarone long-term for atrial fibrillation should be routinely
screened for which adverse effect?
A. Pulmonary toxicity and thyroid dysfunction
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
, B. Severe hypoglycemia
C. Acute interstitial nephritis
D. Aplastic anemia
Correct Answer: D
Rationale: Amiodarone is associated with pulmonary fibrosis, hypo- and hyperthyroidism due to its
iodine content, and requires periodic chest radiographs, PFTs, and thyroid function tests. This is a core
monitoring principle in advanced cardiovascular pharmacology.
4. In a patient with diabetes and albuminuria, the preferred initial antihypertensive class
according to current guidelines is:
A. Dihydropyridine calcium channel blocker
B. Thiazide-like diuretic
C. ACE inhibitor or angiotensin receptor blocker
D. Beta-blocker without intrinsic sympathomimetic activity
Correct Answer: C
Rationale: ACE inhibitors or ARBs are first-line for patients with diabetes and albuminuria because of
proven renoprotective effects independent of blood-pressure lowering, as supported by ADA Standards
of Care and KDIGO guidelines.
5. Which statement best describes the mechanism of action of digoxin in heart failure?
A. Inhibition of Na+/K+-ATPase leading to increased intracellular calcium
B. Blockade of beta-1 adrenergic receptors
C. Activation of guanylate cyclase to increase cGMP
D. Selective inhibition of the funny current (If) in the SA node
Correct Answer: C
Rationale: Digoxin inhibits the sodium-potassium ATPase pump, raising intracellular sodium, which
reduces calcium extrusion via the Na/Ca exchanger and thereby increases contractile force. This classic
mechanism remains relevant for rate control and selected HFrEF cases.
6. A patient with type 2 diabetes is prescribed semaglutide. The AGPCNP counsels that the
most common gastrointestinal adverse effect is:
A. Constipation requiring osmotic laxatives
B. Nausea that often improves with dose titration
C. Severe pancreatitis in the majority of users
D. Irreversible gastroparesis
Correct Answer: D
Rationale: GLP-1 receptor agonists commonly cause nausea, vomiting, and delayed gastric emptying,
especially during titration. Slow dose escalation and patient education minimize discontinuation,
consistent with ADA pharmacologic approaches.
7. Which of the following antiarrhythmic agents is classified as a pure class III agent that
prolongs the action potential primarily by blocking potassium channels?
A. Flecainide
B. Lidocaine
C. Dofetilide
D. Verapamil
Correct Answer: B
Rationale: Dofetilide is a pure class III agent that blocks the rapid component of the delayed rectifier
potassium current (IKr), prolonging repolarization. It requires inpatient initiation and QTc monitoring,
a key prescribing safety point.
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
,8. When converting a patient from oral warfarin to a direct oral anticoagulant (DOAC) for
nonvalvular atrial fibrillation, the AGPCNP should:
A. Discontinue warfarin and start the DOAC when INR is ≤2.0
B. Overlap warfarin and DOAC for a minimum of 7 days
C. Start the DOAC only after a 48-hour washout period regardless of INR
D. Continue both agents indefinitely for dual therapy
Correct Answer: A
Rationale: Per product labeling and ACC/AHA guidance, DOACs are typically initiated when INR falls
to ≤2.0 after warfarin discontinuation to minimize thromboembolic risk while avoiding excess
anticoagulation.
9. A patient with hypothyroidism is well controlled on levothyroxine. Which concurrent
medication is most likely to require an increased levothyroxine dose?
A. Ferrous sulfate taken at the same time
B. Metformin
C. Lisinopril
D. Atorvastatin
Correct Answer: D
Rationale: Iron salts, calcium, and certain resins bind levothyroxine in the gut and reduce absorption
when co-administered. Separating administration by several hours or increasing the dose may be
necessary.
10. In the management of acute decompensated heart failure with volume overload, the
preferred initial intravenous diuretic is:
A. Hydrochlorothiazide
B. Spironolactone
C. Furosemide or another loop diuretic
D. Acetazolamide
Correct Answer: A
Rationale: Loop diuretics remain first-line for acute volume overload because of their rapid onset and
efficacy even in reduced GFR. This is standard in AHA/ACC heart-failure guidelines and advanced
pharmacology curricula.
11. Which of the following best explains the cardioprotective effect of mineralocorticoid
receptor antagonists in HFrEF?
A. Direct positive inotropy
B. Reduction of myocardial fibrosis and aldosterone-mediated remodeling
C. Selective coronary vasodilation
D. Inhibition of hepatic cholesterol synthesis
Correct Answer: D
Rationale: Spironolactone and eplerenone block aldosterone receptors, decreasing sodium retention,
potassium loss, and deleterious cardiac remodeling/fibrosis, improving outcomes in HFrEF as
demonstrated in RALES and EMPHASIS-HF.
12. A patient with type 2 diabetes and established atherosclerotic cardiovascular disease
should preferentially receive which glucose-lowering agent for secondary prevention
benefit?
A. Sulfonylurea
B. DPP-4 inhibitor
C. GLP-1 receptor agonist or SGLT2 inhibitor with proven CV benefit
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
, D. Meglitinide
Correct Answer: C
Rationale: ADA and AHA guidelines recommend GLP-1 RAs or SGLT2 inhibitors with demonstrated
cardiovascular risk reduction for patients with T2DM and established ASCVD, independent of glycemic
control.
13. The primary mechanism by which ezetimibe lowers LDL cholesterol is:
A. Inhibition of HMG-CoA reductase
B. Blockade of NPC1L1-mediated cholesterol absorption in the intestine
C. Activation of PPAR-alpha
D. Inhibition of PCSK9
Correct Answer: B
Rationale: Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter, reducing intestinal
cholesterol absorption. It is often added to statin therapy for further LDL lowering per ACC/AHA lipid
guidelines.
14. Which laboratory abnormality is most characteristic of thiazide-induced electrolyte
disturbance?
A. Hyperkalemia and hyponatremia
B. Hypokalemia, hyponatremia, and hyperuricemia
C. Hypercalcemia and hyperkalemia
D. Hypomagnesemia only without other changes
Correct Answer: D
Rationale: Thiazides commonly cause hypokalemia, hyponatremia, hyperuricemia, and mild
hypercalcemia. Monitoring electrolytes is essential, especially in older adults.
15. A patient with atrial fibrillation and a CHA2DS2-VASc score of 4 is prescribed apixaban.
The standard dose for most adults with normal renal function is:
A. 5 mg twice daily
B. 2.5 mg twice daily for all patients
C. 15 mg once daily
D. 20 mg once daily with the evening meal
Correct Answer: A
Rationale: Apixaban 5 mg BID is the standard dose; the 2.5 mg BID dose is reserved for patients
meeting at least two of three criteria (age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL).
16. Which of the following insulin regimens most closely mimics physiologic basal-bolus
secretion?
A. NPH insulin twice daily alone
B. Long-acting basal insulin plus prandial rapid-acting insulin
C. Regular insulin three times daily without basal coverage
D. Premixed 70/30 insulin once daily
Correct Answer: B
Rationale: Basal-bolus therapy with a long-acting analog (e.g., glargine, degludec) plus rapid-acting
analogs at meals most closely approximates normal insulin physiology and is preferred for intensive
management.
17. The AGPCNP recognizes that ranolazine is primarily indicated for:
A. Acute coronary syndrome reperfusion
B. Chronic stable angina refractory to other antianginal agents
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
Final Actual Exam (Weeks 5–8) 2026/2027 |
Verified Questions
Chamberlain University College of Nursing | Verified Q&A | Graduate-Level Adult-
Gerontology Primary Care Nurse Practitioner Students
This comprehensive final actual exam set contains exactly 200 original questions designed to reinforce
the official NR 568 Advanced Pharmacology course objectives for Weeks 5–8. The questions rigorously
assess mastery of Cardiovascular and Endocrine Pharmacology; Respiratory, Gastrointestinal, and
Infectious Disease Pharmacology; Neurological, Psychiatric, and Pain Management Pharmacology; and
Geriatric Pharmacology, Polypharmacy, and Safe Prescribing Principles. Content is original and
constructed to promote advanced clinical prescribing proficiency, evidence-based decision-making, and
patient safety for Graduate-Level Adult-Gerontology Primary Care Nurse Practitioner students preparing
for the final actual examination in the 2026/2027 academic cycle. Rationales draw upon foundational
advanced pharmacology textbooks and current clinical practice guidelines from organizations such as the
AHA, ADA, IDSA, GOLD, GINA, AGS, and others.
Domain: Cardiovascular and Endocrine Pharmacology
1. A 68-year-old patient with heart failure with reduced ejection fraction is started on
sacubitril/valsartan. The AGPCNP understands that this agent’s primary mechanism
involves:
A. Selective beta-1 blockade reducing myocardial oxygen demand
B. Neprilysin inhibition combined with angiotensin receptor blockade
C. Direct inhibition of the sodium-potassium ATPase pump
D. Calcium channel blockade in vascular smooth muscle
Correct Answer: B
Rationale: Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor (ARNI). Sacubitril
inhibits neprilysin, increasing natriuretic peptides, while valsartan blocks AT1 receptors. This dual
action is guideline-directed for HFrEF per AHA/ACC recommendations and is covered in advanced
pharmacology curricula for heart failure management.
2. Which laboratory parameter requires the closest monitoring when initiating
dapagliflozin in a patient with type 2 diabetes and chronic kidney disease?
A. Serum potassium and estimated glomerular filtration rate
B. Fasting lipid profile
C. Serum calcium and phosphate
D. Thyroid-stimulating hormone
Correct Answer: A
Rationale: SGLT2 inhibitors such as dapagliflozin can cause volume depletion and modest declines in
eGFR upon initiation; potassium may also shift. Monitoring eGFR and electrolytes aligns with ADA and
KDIGO guidance and is emphasized in NR 568 endocrine and cardiovascular content.
3. A patient taking amiodarone long-term for atrial fibrillation should be routinely
screened for which adverse effect?
A. Pulmonary toxicity and thyroid dysfunction
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
, B. Severe hypoglycemia
C. Acute interstitial nephritis
D. Aplastic anemia
Correct Answer: D
Rationale: Amiodarone is associated with pulmonary fibrosis, hypo- and hyperthyroidism due to its
iodine content, and requires periodic chest radiographs, PFTs, and thyroid function tests. This is a core
monitoring principle in advanced cardiovascular pharmacology.
4. In a patient with diabetes and albuminuria, the preferred initial antihypertensive class
according to current guidelines is:
A. Dihydropyridine calcium channel blocker
B. Thiazide-like diuretic
C. ACE inhibitor or angiotensin receptor blocker
D. Beta-blocker without intrinsic sympathomimetic activity
Correct Answer: C
Rationale: ACE inhibitors or ARBs are first-line for patients with diabetes and albuminuria because of
proven renoprotective effects independent of blood-pressure lowering, as supported by ADA Standards
of Care and KDIGO guidelines.
5. Which statement best describes the mechanism of action of digoxin in heart failure?
A. Inhibition of Na+/K+-ATPase leading to increased intracellular calcium
B. Blockade of beta-1 adrenergic receptors
C. Activation of guanylate cyclase to increase cGMP
D. Selective inhibition of the funny current (If) in the SA node
Correct Answer: C
Rationale: Digoxin inhibits the sodium-potassium ATPase pump, raising intracellular sodium, which
reduces calcium extrusion via the Na/Ca exchanger and thereby increases contractile force. This classic
mechanism remains relevant for rate control and selected HFrEF cases.
6. A patient with type 2 diabetes is prescribed semaglutide. The AGPCNP counsels that the
most common gastrointestinal adverse effect is:
A. Constipation requiring osmotic laxatives
B. Nausea that often improves with dose titration
C. Severe pancreatitis in the majority of users
D. Irreversible gastroparesis
Correct Answer: D
Rationale: GLP-1 receptor agonists commonly cause nausea, vomiting, and delayed gastric emptying,
especially during titration. Slow dose escalation and patient education minimize discontinuation,
consistent with ADA pharmacologic approaches.
7. Which of the following antiarrhythmic agents is classified as a pure class III agent that
prolongs the action potential primarily by blocking potassium channels?
A. Flecainide
B. Lidocaine
C. Dofetilide
D. Verapamil
Correct Answer: B
Rationale: Dofetilide is a pure class III agent that blocks the rapid component of the delayed rectifier
potassium current (IKr), prolonging repolarization. It requires inpatient initiation and QTc monitoring,
a key prescribing safety point.
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
,8. When converting a patient from oral warfarin to a direct oral anticoagulant (DOAC) for
nonvalvular atrial fibrillation, the AGPCNP should:
A. Discontinue warfarin and start the DOAC when INR is ≤2.0
B. Overlap warfarin and DOAC for a minimum of 7 days
C. Start the DOAC only after a 48-hour washout period regardless of INR
D. Continue both agents indefinitely for dual therapy
Correct Answer: A
Rationale: Per product labeling and ACC/AHA guidance, DOACs are typically initiated when INR falls
to ≤2.0 after warfarin discontinuation to minimize thromboembolic risk while avoiding excess
anticoagulation.
9. A patient with hypothyroidism is well controlled on levothyroxine. Which concurrent
medication is most likely to require an increased levothyroxine dose?
A. Ferrous sulfate taken at the same time
B. Metformin
C. Lisinopril
D. Atorvastatin
Correct Answer: D
Rationale: Iron salts, calcium, and certain resins bind levothyroxine in the gut and reduce absorption
when co-administered. Separating administration by several hours or increasing the dose may be
necessary.
10. In the management of acute decompensated heart failure with volume overload, the
preferred initial intravenous diuretic is:
A. Hydrochlorothiazide
B. Spironolactone
C. Furosemide or another loop diuretic
D. Acetazolamide
Correct Answer: A
Rationale: Loop diuretics remain first-line for acute volume overload because of their rapid onset and
efficacy even in reduced GFR. This is standard in AHA/ACC heart-failure guidelines and advanced
pharmacology curricula.
11. Which of the following best explains the cardioprotective effect of mineralocorticoid
receptor antagonists in HFrEF?
A. Direct positive inotropy
B. Reduction of myocardial fibrosis and aldosterone-mediated remodeling
C. Selective coronary vasodilation
D. Inhibition of hepatic cholesterol synthesis
Correct Answer: D
Rationale: Spironolactone and eplerenone block aldosterone receptors, decreasing sodium retention,
potassium loss, and deleterious cardiac remodeling/fibrosis, improving outcomes in HFrEF as
demonstrated in RALES and EMPHASIS-HF.
12. A patient with type 2 diabetes and established atherosclerotic cardiovascular disease
should preferentially receive which glucose-lowering agent for secondary prevention
benefit?
A. Sulfonylurea
B. DPP-4 inhibitor
C. GLP-1 receptor agonist or SGLT2 inhibitor with proven CV benefit
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
, D. Meglitinide
Correct Answer: C
Rationale: ADA and AHA guidelines recommend GLP-1 RAs or SGLT2 inhibitors with demonstrated
cardiovascular risk reduction for patients with T2DM and established ASCVD, independent of glycemic
control.
13. The primary mechanism by which ezetimibe lowers LDL cholesterol is:
A. Inhibition of HMG-CoA reductase
B. Blockade of NPC1L1-mediated cholesterol absorption in the intestine
C. Activation of PPAR-alpha
D. Inhibition of PCSK9
Correct Answer: B
Rationale: Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter, reducing intestinal
cholesterol absorption. It is often added to statin therapy for further LDL lowering per ACC/AHA lipid
guidelines.
14. Which laboratory abnormality is most characteristic of thiazide-induced electrolyte
disturbance?
A. Hyperkalemia and hyponatremia
B. Hypokalemia, hyponatremia, and hyperuricemia
C. Hypercalcemia and hyperkalemia
D. Hypomagnesemia only without other changes
Correct Answer: D
Rationale: Thiazides commonly cause hypokalemia, hyponatremia, hyperuricemia, and mild
hypercalcemia. Monitoring electrolytes is essential, especially in older adults.
15. A patient with atrial fibrillation and a CHA2DS2-VASc score of 4 is prescribed apixaban.
The standard dose for most adults with normal renal function is:
A. 5 mg twice daily
B. 2.5 mg twice daily for all patients
C. 15 mg once daily
D. 20 mg once daily with the evening meal
Correct Answer: A
Rationale: Apixaban 5 mg BID is the standard dose; the 2.5 mg BID dose is reserved for patients
meeting at least two of three criteria (age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL).
16. Which of the following insulin regimens most closely mimics physiologic basal-bolus
secretion?
A. NPH insulin twice daily alone
B. Long-acting basal insulin plus prandial rapid-acting insulin
C. Regular insulin three times daily without basal coverage
D. Premixed 70/30 insulin once daily
Correct Answer: B
Rationale: Basal-bolus therapy with a long-acting analog (e.g., glargine, degludec) plus rapid-acting
analogs at meals most closely approximates normal insulin physiology and is preferred for intensive
management.
17. The AGPCNP recognizes that ranolazine is primarily indicated for:
A. Acute coronary syndrome reperfusion
B. Chronic stable angina refractory to other antianginal agents
NR 568 Advanced Pharmacology for AGPCNP Final Actual Exam (Weeks 5–8) 2026/2027 | Verified Questions
